Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Vepafestinib |
Synonyms | |
Therapy Description |
Vepafestinib (TAS0953/HM06) is a selective, ATP-competitive RET inhibitor with activity against RET fusions and V804 and G810 mutants, which may result in decreased tumor cell growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P06-02; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P233). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Vepafestinib | TAS0953/HM06 | RET Inhibitor 53 | Vepafestinib (TAS0953/HM06) is a selective, ATP-competitive RET inhibitor with activity against RET fusions and V804 and G810 mutants, which may result in decreased tumor cell growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P06-02; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P233). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET C634W | medullary thyroid carcinoma | sensitive | Vepafestinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vepafestinib (TAS0953/HM06) inhibited proliferation of a medullary thyroid cancer cell line harboring RET C634W in culture (PMID: 37743366). | 37743366 |
RET M918T | Advanced Solid Tumor | sensitive | Vepafestinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vepafestinib (TAS0953/HM06) inhibited proliferation of cells expressing RET M918T in culture (PMID: 37743366). | 37743366 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04683250 | Phase Ib/II | Vepafestinib | Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities ((MARGARET)) | Recruiting | USA | 1 |